How Indian pharma companies should have dealt with Remdesivir crisis
Incidentally, pharma companies have been conspicuous by their silence, busy making hay while the sun shines. Except for disseminating helpline numbers or web-links to check the availability of the medicine stock — measures that havent helped much during the peak of the second wave —the companies did little to stem the crisis. Instead, they became part of the problem as they faltered in their role of patients outreach and doctor education.